Dinshaw Irani’s top sectoral picks for next market cycle
«We like the CDMO space, no doubt about that and that is why we have only one player out there, which is probably one of the best players within that space as such,» says Dinshaw Irani, CEO, Helios Mutual Fund.
Are you keen on pharma at all and which end of pharma, is it hospitals, diagnostic, domestic facing companies, CDMO players, export players, where is that you are finding value and comfort right now?
Dinshaw Irani: So, basically, it is kitchen sinking out there. I mean, the way you stated. So, I do not know. We are very keen on obviously hospitals. We have got a couple of players there that we like and that is more of a call on the per capita is moving up in our country and obviously health becoming a bigger spend, that is what one saw in China or any other economy which was picking up as such, so that is one call that we have taken.
We like the CDMO space, no doubt about that and that is why we have only one player out there, which is probably one of the best players within that space as such.
And obviously the US facing pharma, if you take a Trump call, there is definitely going to be a pressure going forward as such, so that is why we do not like the US focused pharma companies much and we do not have much exposure there, rather no exposure there as such. We are more focused on to domestic pharma. In a diagnostic space, we got the best player, the top player with us.
With every two-three quarters the leadership in the market changes. What does well this year, rarely does well for two or three years
